Bridge City Capital LLC Increases Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Bridge City Capital LLC grew its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 65.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 115,855 shares of the company's stock after buying an additional 45,760 shares during the period. Bridge City Capital LLC owned 0.24% of Amphastar Pharmaceuticals worth $3,359,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Boston Partners bought a new stake in shares of Amphastar Pharmaceuticals during the 4th quarter valued at about $15,778,000. Wealthfront Advisers LLC purchased a new stake in Amphastar Pharmaceuticals in the fourth quarter valued at approximately $9,268,000. Systematic Financial Management LP purchased a new stake in Amphastar Pharmaceuticals in the fourth quarter valued at approximately $9,147,000. Dimensional Fund Advisors LP lifted its position in Amphastar Pharmaceuticals by 9.6% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,198,590 shares of the company's stock valued at $44,503,000 after purchasing an additional 105,288 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. grew its stake in Amphastar Pharmaceuticals by 402.4% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 118,851 shares of the company's stock worth $4,413,000 after buying an additional 95,192 shares in the last quarter. Institutional investors own 65.09% of the company's stock.

Amphastar Pharmaceuticals Stock Up 1.5%

Amphastar Pharmaceuticals stock traded up $0.39 during trading hours on Thursday, hitting $26.44. The stock had a trading volume of 506,968 shares, compared to its average volume of 487,861. The stock has a market capitalization of $1.25 billion, a P/E ratio of 8.81, a price-to-earnings-growth ratio of 2.19 and a beta of 0.77. Amphastar Pharmaceuticals, Inc. has a 12-month low of $22.64 and a 12-month high of $53.96. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. The stock's 50-day moving average price is $24.60 and its 200-day moving average price is $31.22.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. Piper Sandler reduced their price target on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a research report on Friday, March 21st. Wells Fargo & Company reduced their price objective on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating on the stock in a research note on Thursday, May 8th. JPMorgan Chase & Co. reissued a "neutral" rating and issued a $30.00 target price (down previously from $45.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, May 12th. Finally, Needham & Company LLC restated a "hold" rating on shares of Amphastar Pharmaceuticals in a report on Thursday, April 10th. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $32.33.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.